Influence of oral contraceptives and pregnancy on constituents of the kallikrein-kininogen system in plasma.
We measured kininogens of low and high molecular mass along with prokallikrein activity in plasma of women with a normal menstrual cycle. We observed no difference between results for the follicular and luteal phases. We assayed the same constituents in women who were taking oral contraceptives (combined estroprogestative) and found that activity of prokallikrein and concentrations of low- and high-molecular-mass kininogens were significantly increased. Lastly, we studied the components of the kallikrein-kininogen system during pregnancy. We also observed a marked increase in their concentrations in plasma, despite a decrease in total proteins. Specifically, prokallikrein and kininogens increase continuously with gestational age, reaching their maxima around the eighth month of pregnancy. At that time, more than 50% of observed results fall outside the normal reference interval. Our observations are even more striking when prokallikrein and kininogens are expressed in units per gram of total proteins, to account for the hemodilution. After delivery, the concentrations of prokallikrein and low- and high-molecular-mass kininogens decline promptly, returning to normal within three days.
D000328:Adult; D003276:Contraceptives, Oral / Q000494:pharmacology*; D005260:Female; D005865:Gestational Age; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D007704:Kininogens / Q000097:blood*; D007743:Labor, Obstetric; D008597:Menstrual Cycle; D008970:Molecular Weight; D011247:Pregnancy
D003276:Contraceptives, Oral; D007704:Kininogens; D007610:Kallikreins